Ipsen studies show further benefits of Dysport

Ipsen has announced the publication of new clinical data showing how its drug Dysport can benefit adult patients with lower limb spasticity following a stroke or traumatic brain injury.

Detailed results from a phase III placebo-controlled trial and its open-label extension study have been published in the medical journal Neurology, both of which demonstrate the efficacy and safety of the drug in this indication.

Among adults with hemiparesis who experienced lower limb spasticity, Dysport was shown to have a positive impact on muscle tone, while repeated administration over a year was well-tolerated and improved both walking speed and the likelihood of achieving community ambulation.

Data from these studies helped to secure US approval for the therapy in the treatment of spasticity in adults earlier this year, with marketing authorisation processes in other key territories – including the UK and Germany – still ongoing.

Alexandre Lebeaut, executive vice-president for research and development and chief scientific officer of Ipsen, said: "The results of the phase III studies (double-blind and open-label) published this month in Neurology underline the significant clinical benefit for adult patients with lower limb spasticity who received repeated injections of Dysport."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.